EGFR and neoplasm: For instance, inhibition of PRMT1 or treatment with PRMT1 inhibitors (e.g., AMI-1, C7280948) increases tumor sensitivity to the EGFR monoclonal antibody cetuximab and to PARP inhibitors such as olaparib [593, 594].